Monday, 1 May 2017
Latest news
Main » Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) PT Suggests Stock Is Worth Around $4.50

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) PT Suggests Stock Is Worth Around $4.50

02 February 2017

The stock as of last trading session moved 16.67% up from its 52 week low and was -28.70% behind its 52 week high. (NASDAQ:ARNA) reported its EPS in the last quarter as $-0.05/Share beating the analyst estimate of $-0.07/Share by the difference of $0.02. (NASDAQ:ACHN) in which Wedbush Initiates Coverage on Achillion Pharmaceuticals, Inc. The company has a market cap of $391.73M and now has 243.31M shares outstanding. They now have a United States dollars 16 price target on the stock. JMP Securities Upgrades Achillion Pharmaceuticals, Inc. There may be various price targets for a stock.

02/25/2016 - Achillion Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at Maxim Group. The stock now has a consensus rating of "Buy" and a consensus price target of $9.88. The shares have been given a mean Overweight rating keeping in view the consensus of 7 Analysts. They now have a United States dollars 11.5 price target on the stock.

The financial terms of the revised agreement are expected to provide Arena with $23 million of cash payments and over $80 million of potential cost relief on current lorcaserin development obligations. They now have a United States dollars 20 price target on the stock.

Shares of Achillion Pharmaceuticals Inc.

09/08/2015 - Achillion Pharmaceuticals, Inc. was upgraded to "buy" by analysts at UBS.

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms.

09/04/2014 - Credit Suisse began new coverage on Arena Pharmaceuticals, Inc. giving the company a "underperform" rating. They now have a United States dollars 22.5 price target on the stock.

04/25/2014 - Wells Fargo began new coverage on Arena Pharmaceuticals, Inc. giving the company a "market perform" rating.

11/06/2015 - Achillion Pharmaceuticals, Inc. had its "hold" rating reiterated by analysts at Jefferies. They now have a United States dollars 12 price target on the stock.

05/22/2015 - Achillion Pharmaceuticals, Inc. was upgraded to "buy" by analysts at Zacks. Finally, Leerink Swann reissued a "market perform" rating on shares of Achillion Pharmaceuticals in a research note on Thursday, November 3rd. The stock is now moving above its 20-Day Simple Moving Average of 5.31% with the 50-Day Simple Moving Average of 5.31 percent.

Amgen Inc. (AMGN) recently recorded 1.91 percent change and now at $159.67 is 20.28 percent away from its 52-week low and down -9.1 percent versus its peak.

Arena Pharmaceuticals, Inc. has 1 year price target of $4.5.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir. ABP 501 has been recommended for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, non-infectious intermediate, posterior and panuveitis, moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication (s).